BRIEF REPORT Osteoporosis Associated with Neutralizing Autoantibodies against Osteoprotegerin

被引：70

作者：

Riches, Philip L. ^{[1
]}

McRorie, Euan ^{[1
]}

Fraser, William D. ^{[2
]}

Determann, Catherine ^{[1
]}

van't Hof, Rob ^{[1
]}

Ralston, Stuart H. ^{[1
]}

机构：

[1] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland

[2] Univ Liverpool, Sch Clin Sci, Unit Clin Chem, Liverpool L69 3BX, Merseyside, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 15期

关键词：

BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CELIAC-DISEASE; PAGETS-DISEASE; MUTATIONS; CALCIUM; RANKL;

D O I：

10.1056/NEJMoa0810925

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-kappa B (RANK), were identified in a man with celiac disease who presented with severe osteoporosis and high bone turnover. The osteoporosis did not respond to the treatment of his celiac disease but was completely reversed by bisphosphonate therapy. Autoantibodies against osteoprotegerin were detected in three additional patients with celiac disease. Such autoantibodies may be associated with the development of high-turnover osteoporosis, but whether autoantibodies against osteoprotegerin commonly contribute to the pathogenesis of osteoporosis in patients with celiac disease remains to be determined.

引用

页码：1459 / 1465

页数：7

共 16 条

[1]

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].